Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.73 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.73 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.73 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794421 | 0.95 | CACNA2D1 (0.66) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL4279734 | 0.86 | TACR2 (0.60) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL2795615 | 0.85 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL3861078 | 0.84 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1CTDP1 | |
| SCHEMBL2794338 | 0.82 | CACNA2D1 (0.50) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL10335011 | 0.82 | MEN1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 | |
| SCHEMBL2792145 | 0.81 | CACNA2D1 (0.48) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM1 | |
| SCHEMBL4275822 | 0.81 | CACNA2D1 (0.69) | CACNA2D1CACNA1BCACNB1CACNA1CCHRM1 | |
| SCHEMBL4286091 | 0.81 | CACNA2D1 (0.71) | CACNA2D1CACNA1BCACNB1CACNA1CGRM7 | |
| SCHEMBL4284711 | 0.81 | CACNA2D1 (0.71) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | claimed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | claimed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | CACNA2D1 45/4885CACNA1B 5/4885CACNB1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.